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vested and spliced longitudinally to be used as an inter-
position cuff between the IVC and LRV. A partial-
occlusion clamp was then placed across the IVC-LRV
junction. The LRV was divided and the venotomy on the
IVC was extended inferiorly. The superior portion of the
IVC venotomy was sutured. Subsequently, the LRV was
then anastomosed caudally onto the IVC in and end-to-
side fashion with the vein cuff bridging the gap.
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Objectives: Acute limb ischemia (ALI) in infants is a
catastrophic event usually associated with other life
threatening medical problems. Since ALI is rare in the
infant population it presents a clinical conundrum for the
vascular surgeon with regards to management. Here we
report our experience in the management of infant ALI
to provide management guidelines for the vascular
surgeon.
Methods: Retrospective analysis of our vascular sur-
gery database from 2004 - 2010 of infants diagnosed with
ALI.
Results: Twelve infants with a mean age of 3  3
months were identified. There were 11 iatrogenic injuries
and 1 unknown cause of ALI. The most frequent presen-
tations were cyanotic limbs (n8) and pulselessness (n6).
The lower extremities were most commonly involved
(n9). The most common arterial sites of occlusion were
CFA (n6), SFA (n3), and radial arteries (n2).
Eleven patients were treated conservatively with systemic
heparin (n8), intra-muscular enoxaparin (n2) and
anti-platelet treatment (n1). One patient was treated
surgically with Fogarty balloon thrombectomy of the
CFA. There were three deaths all due to associated
comorbidities. The one surgically managed patient died
30 days after intervention due to septic complications.
Follow up was available on seven of nine survivors. All
had palpable pulses present and viable limbs on fol-
low-up examination (mean 20  14 months, range
5-42). There were three complications in the patients
managed conservatively: loss of fingernails (1), skin ne-
crosis requiring debridement (1), and maldevelopment
of the foot (1). None of the patients required amputa-
tion due to conservative management.
Conclusions: Limb viability was 100% in this series of
infant ALI managed non-operatively, which reflects the po-
tential of collateral vessel formation and recanalization of
thrombosed vessels in this patient population. Our recom-
mendation for infants presenting with ALI is conservative
observation with anti-coagulation and intervention only for
cases with tissue loss.
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Objectives: The randomized DECREASE III trial
showed that perioperative statin use is associated with a
significant reduction of perioperative cardiovascular
events. However, the potential long-term benefit of
starting statins preoperatively is not well described. The
aim of this study was to establish whether preoperative
initation of statin therapy also results in a long-term
survival benefit compared to postoperative initiation of
statin therapy.
Methods: The DECREASE III trial was a double blind
randomized trial including vascular surgery patients, compar-
ing placebo and fluvastatin use in the perioperative period.
Treatment started amedian of 34 days prior to surgery. At the
end of the study period, i.e. at the outpatient clinic visit 30
days after surgery, all patients were prescribed life-long statins
as recommended by current guidelines. The endpoint of the
current analysis was all-cause death, ascertained by contacting
the civil service registry.
Figure 1. Long-term outcome of patients on perioperative statin
therapy vs placebo.
JOURNAL OF VASCULAR SURGERY
June Supplement 201120S Abstracts
Results: A total of 497 patients were randomized, 247
to placebo and 250 to fluvastatin. Perioperative statin use
was associated with a significant reduction of perioperative
cardiovascular events (HR 0.55; 95% CI 0.34 - 0.88).
During a median follow-up of 4.8 years, 129 patients died.
In multivariate analysis, adjusting for possible confounders
including cardiovascular risk factors, type and site of vascu-
lar surgery and age, preoperative statin initiation was asso-
ciated with an improved long-term outcome (HR 0.59,
95%CI 0.41-0.84, p0.004, figure 1). This might be due
to the prevention of perioperative myocardial damage as
patients with myocardial damage had a significant higher
risk of death during follow-up (HR 2.19, 95% CI 1.40 -
3.41, p0.001, figure 2).
Conclusions: There appears to be a “legacy” effect of
perioperative statin therapy. Starting statins preoperatively
results in an improved long-term survival compared to
starting statins after the vascular surgery procedure.
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Objectives:This study explores the fiduciary advantage
of a vascular surgery program to an individual hospital. We
will exemplify the effects of the services provided by track-
ing downstream and spin-off revenue as a means to culti-
vate financial equipoise.
Methods: This is a retrospective review of a single,
tertiary care center’s databases that maintain diagnosis-
related group (DRG) codes, associated current procedural
terminology (CPT) codes, revenue, and costs from April
2009 to September 2010. Inclusion criteria for analysis
were patients with zero or one prior interface with the
hospital before accessing services through the Vascular
Surgery Division. Accounts that were not paid or had
incomplete data were excluded as well as DRGs with a low
volume of patients. The primary outcome measure is the
average net margin across DRGs. The secondary outcomes
are the impact on interfaces with other physician or hospi-
tal-based services and the associated revenue.
Results: 137 patients unique to the vascular surgery
service were identified. These patients accounted for 4700
hospital and physician encounters, creating $5 million in
primary and downstream revenue. This patient subset ac-
cessed 28 hospital-based specialties and 30 physician spe-
cialties in 18 months. Three percent of total admissions
were attributable to the vascular surgery service, accounting
for an average DRG weight of 2.17 in the Northeastern
region. We also identified the most and least profitable
DRGs within this health system and corresponding payer
mix. “Other vascular procedures” (DRG252) generated an
average positive net margin of $7360 per encounter. Am-
putation (DRG 241) had the greatest loss with negative
$4084 per encounter. Overall, vascular DRGs generated a
net positive margin of $509,000.
Conclusions: This study demonstrates that new vascu-
lar surgical referrals are a significant catalyst of downstream
revenue and persistent positive utilization of both hospital
and physician based resources.
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Objectives: To compare the outcome between open
and endovascular repair of acute traumatic rupture of the
thoracic aorta.
Methods: Seventy-five patients (mean age 38.6 /
10.7 years) with an acute traumatic aortic rupture were
referred to our hospital between January 1990 andNovem-
ber 2010. Thirty-six patients (34men,mean age 34.2/
10.8 years) underwent surgical repair using cardiopulmo-
nary bypass. Endovascular repair was performed in 45
Figure 2. Long-term outcome of patients with or without peri-
operative myocardial ischemia.
JOURNAL OF VASCULAR SURGERY
Volume 53, Number 17S Abstracts 21S
